MA43835A - Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires - Google Patents

Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires

Info

Publication number
MA43835A
MA43835A MA043835A MA43835A MA43835A MA 43835 A MA43835 A MA 43835A MA 043835 A MA043835 A MA 043835A MA 43835 A MA43835 A MA 43835A MA 43835 A MA43835 A MA 43835A
Authority
MA
Morocco
Prior art keywords
intermediaries
pegylated
preparation
medicinal products
medicinal
Prior art date
Application number
MA043835A
Other languages
English (en)
Inventor
Anusuya Choudhury
Wendel Doubleday
Yunyu Mao
Philip Moquist
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MA43835A publication Critical patent/MA43835A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043835A 2016-03-25 2017-03-24 Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires MA43835A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662313460P 2016-03-25 2016-03-25

Publications (1)

Publication Number Publication Date
MA43835A true MA43835A (fr) 2018-11-28

Family

ID=59900804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043835A MA43835A (fr) 2016-03-25 2017-03-24 Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires

Country Status (15)

Country Link
US (2) US11844839B2 (fr)
EP (1) EP3433278A4 (fr)
JP (4) JP7073266B2 (fr)
KR (2) KR102626498B1 (fr)
CN (1) CN109843919A (fr)
AU (1) AU2017237186B2 (fr)
BR (1) BR112018069273A2 (fr)
CA (1) CA3017527A1 (fr)
EA (1) EA201892040A1 (fr)
IL (2) IL261759B (fr)
MA (1) MA43835A (fr)
SG (1) SG11201807827VA (fr)
TW (2) TWI790996B (fr)
UA (1) UA125510C2 (fr)
WO (1) WO2017165851A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7073266B2 (ja) * 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
CA3041254A1 (fr) 2016-10-19 2018-04-26 Invenra Inc. Constructions d'anticorps
MY199937A (en) 2016-11-08 2023-11-29 Regeneron Pharma Steroids and protein-conjugates thereof
BR112019013107A2 (pt) 2016-12-22 2019-12-17 Univ Degli Studi Magna Graecia Catanzaro anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
KR102648564B1 (ko) * 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CN111601619A (zh) * 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
US12070506B2 (en) 2018-01-08 2024-08-27 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
WO2019234136A1 (fr) 2018-06-05 2019-12-12 King's College London Constructions de ciblage btnl3/8 pour l'administration de charges utiles au système gastro-intestinal
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
EP4400121A1 (fr) 2021-09-03 2024-07-17 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP4483907A1 (fr) * 2022-02-25 2025-01-01 ABTIS Co., Ltd. Nouveau conjugué anticorps-médicament
EP4548932A1 (fr) 2022-06-30 2025-05-07 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prévention du cancer
CN120417937A (zh) 2022-11-17 2025-08-01 赛诺菲 Ceacam5抗体-药物缀合物及其使用方法
EP4601703A1 (fr) 2023-04-18 2025-08-20 Astrazeneca AB Conjugués comprenant des lieurs clivables
WO2025002368A1 (fr) 2023-06-29 2025-01-02 Beigene, Ltd. Conjugués bioactifs, leur procédé de préparation et leur utilisation

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1213229A (fr) 1982-04-12 1986-10-28 Gary S. David Anticorps a specificite double, leur preparation et leurs usages
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993010260A1 (fr) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE195127T1 (de) * 1993-09-29 2000-08-15 Nissin Food Products Ltd In stellung 21 substituierte steroide
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
DE19516717A1 (de) 1995-05-06 1996-11-07 Basf Ag Verfahren zur Herstellung von Diarylethanen
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2253904A1 (fr) 1996-05-03 1997-11-13 Immunomedics, Inc. Immunotherapie-cible associee contre le cancer
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
ES2273373T3 (es) 1996-08-02 2007-05-01 Ortho-Mcneil Pharmaceutical, Inc. Polipeptidos que tienen unido a su extremo n un unico polimero soluble al agua.
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998036765A1 (fr) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolement et analyse de la structure des depsipeptides cytostatiques lineaires et des cyclo-depsipeptides cytostatiques dolastatine 16, dolastatine 17, dolastatine 18
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1998049198A1 (fr) 1997-04-30 1998-11-05 Enzon, Inc. Proteines a chaine unique fixant les antigenes capables de glycosylation, production et utilisations de ces dernieres
CA2310892A1 (fr) 1997-11-21 1999-06-03 Human Genome Sciences, Inc. Chemokine alpha-5 (ck.alpha.-5)
GB2381622B (en) 1997-12-17 2003-06-25 Fujitsu Ltd Synchronous dynamic random access memory apparatus
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6323135B1 (en) 1998-12-09 2001-11-27 Advanced Micro Devices, Inc. Method of forming reliable capped copper interconnects/with high etch selectivity to capping layer
JP2000230000A (ja) 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001272017A1 (en) 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP4179771B2 (ja) 2001-06-25 2008-11-12 株式会社デンソー 自動車の乗員保護装置
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100829283B1 (ko) 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
GB0218518D0 (en) 2002-03-22 2002-09-18 Aventis Pharma Inc Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
US20050233949A1 (en) 2002-04-12 2005-10-20 Holick Michael F Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
AU2003295432A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
US7273845B2 (en) 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US7888536B2 (en) 2004-02-13 2011-02-15 Quanta Biodesign, Ltd. Selective and specific preparation of discrete PEG compounds
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US20060003412A1 (en) 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP2087910B1 (fr) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Promédicaments polymères
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
EP1817336B1 (fr) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatines comportant une unite d'acide aminobenzoique au n-terminal
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP2008537673A (ja) 2005-01-31 2008-09-25 ジェネンテック・インコーポレーテッド 抗ｅｐｈｂ２抗体とその使用方法
WO2006088248A1 (fr) 2005-02-18 2006-08-24 Nof Corporation Derive de polyoxyalkylene
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
US8132476B2 (en) 2005-06-20 2012-03-13 Hy-Energy, Llc Method and apparatus for handling small quantities of fluids
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
SI3248613T1 (sl) 2005-07-18 2022-04-29 Seagen Inc. Konjugati beta-glukuronidni linker-zdravilo
WO2007080114A2 (fr) 2006-01-11 2007-07-19 Biotech Igg Ab Conjugué de macromolecule
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (fr) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Conjugués anticorps-médicament modifiés
WO2008025020A2 (fr) 2006-08-25 2008-02-28 Seattle Genetics, Inc. agents de liaison de CD30 et leurs usages
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
BRPI0716823A2 (pt) 2006-09-15 2015-05-26 Enzon Pharmaceuticals Inc Conjunto poliméricos contendo porções positivamente carregadas
BRPI0716808A2 (pt) 2006-09-15 2013-11-05 Enzon Pharmaceuticals Inc Ligantes poliméricos baseados em lisina
WO2008034124A2 (fr) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels
US8288349B2 (en) 2006-11-10 2012-10-16 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
CA2699837C (fr) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Agent se liant a une cible de variant et ses utilisations
US7884869B2 (en) 2007-04-30 2011-02-08 Motorola Mobility, Inc. Assignment of pixel element exposure times in digital camera modules and mobile communication devices
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
CA2693645A1 (fr) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Systemes d'administration de medicament polymere contenant un acide allylique aromatique
US20090016985A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
WO2009012958A2 (fr) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Analogues de la tubulysine d
JP2010536986A (ja) 2007-08-20 2010-12-02 エンゾン ファーマシューティカルズ，インコーポレーテッド ピリジルジスルフィド部分を含有するポリマーリンカー
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
CA2718942A1 (fr) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Conjugues auristatine-lieur de medicament
EP2174947A1 (fr) 2008-09-25 2010-04-14 Universität des Saarlandes Pré-tubulysines bioactives et leur utilisation
KR20110075029A (ko) 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
CA2749115C (fr) 2009-01-09 2022-06-21 Seattle Genetics, Inc. Regimes posologiques hebdomadaires pour des conjugues anticorps anti-cd30 vc-pab-mmae - medicament
JP5657567B2 (ja) 2009-01-12 2015-01-21 ユニヴァーシティ オブ ワシントン 配糖体の２−硫酸化方法
EP3100745B1 (fr) 2009-02-05 2018-04-18 Immunogen, Inc. Nouveaux dérivés de benzodiazépine
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
JP2013505944A (ja) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
EP2486023A4 (fr) 2009-10-06 2014-05-07 Immunogen Inc Conjugués puissants et séquences de liaison hydrophiles
CN102648208B (zh) 2009-11-12 2016-04-27 R&D生技药品有限责任公司 微管蛋白抑制剂
EP2322537A1 (fr) 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Inhibiteurs de tubuline
WO2011072240A1 (fr) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Administration d'un médicament, le témozolomide, dans le cadre d'un traitement systémique du cancer
UA115517C2 (uk) 2010-02-08 2017-11-27 Ейдженсіс, Інк. Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
EP2542576B1 (fr) 2010-03-02 2016-04-20 Seattle Genetics, Inc. Procédés pour cribler des anticorps
CA2794307A1 (fr) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Polymeres modifies pour l'administration de polynucleotides, procede de fabrication, et procedes d'utilisation de ceux-ci
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
CN102869254A (zh) 2010-04-16 2013-01-09 安龙制药公司 腺嘌呤核苷酸类似物聚合共轭物
EP2409983A1 (fr) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Analogues de la tubulysine
CA2819038C (fr) 2010-12-06 2023-10-17 Seattle Genetics, Inc. Anticorps humanises diriges vers liv-1 et leur utilisation pour traiter le cancer
EP2675479B1 (fr) 2011-02-15 2016-01-13 Immunogen, Inc. Dérivés cytotoxiques de benzodiazépine
JP5559439B2 (ja) 2011-02-25 2014-07-23 ロンザ リミテッド タンパク質薬剤接合体のための分枝リンカー
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
WO2013033476A1 (fr) 2011-08-30 2013-03-07 Quanta Biodesign, Ltd. Constructions de peg discret ramifié
MX341524B (es) 2011-09-20 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
CA2850373C (fr) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
BR112014019861A2 (pt) 2012-02-17 2017-07-04 Seattle Genetics Inc anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
US20130225789A1 (en) 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN104662000B (zh) 2012-05-15 2018-08-17 索伦托医疗有限公司 药物偶联物及其偶联方法和用途
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
JP6328648B2 (ja) 2012-10-24 2018-05-23 ポリセリックス・リミテッド 新規薬物−タンパク質コンジュゲート
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
US9430462B2 (en) 2013-07-30 2016-08-30 Edanz Group Ltd. Guided article authorship
NZ758050A (en) * 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US11116847B2 (en) * 2013-12-19 2021-09-14 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
KR20230172035A (ko) 2014-09-11 2023-12-21 씨젠 인크. 삼차 아민-함유 약물 물질의 표적화된 전달
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CA2976740A1 (fr) 2015-03-18 2016-09-22 Seattle Genetics, Inc. Anticorps cd48 et conjugues de ceux-ci
JP7073266B2 (ja) * 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
SG11201900699QA (en) 2016-08-09 2019-02-27 Seattle Genetics Inc Drug conjugates with self-stabilizing linkers having improved physiochemical properties
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물

Also Published As

Publication number Publication date
US11844839B2 (en) 2023-12-19
CN109843919A (zh) 2019-06-04
TW201735919A (zh) 2017-10-16
BR112018069273A2 (pt) 2019-01-22
WO2017165851A1 (fr) 2017-09-28
US20190388546A1 (en) 2019-12-26
AU2017237186A1 (en) 2018-11-01
US20240197889A1 (en) 2024-06-20
JP2023106627A (ja) 2023-08-01
IL261759B (en) 2021-10-31
TWI790996B (zh) 2023-02-01
EA201892040A1 (ru) 2019-04-30
CA3017527A1 (fr) 2017-09-28
UA125510C2 (uk) 2022-04-13
SG11201807827VA (en) 2018-10-30
JP2019512492A (ja) 2019-05-16
EP3433278A4 (fr) 2019-11-06
KR20230135169A (ko) 2023-09-22
TW202325718A (zh) 2023-07-01
IL261759A (en) 2018-10-31
EP3433278A1 (fr) 2019-01-30
KR20180134351A (ko) 2018-12-18
IL287140A (en) 2021-12-01
JP2020100669A (ja) 2020-07-02
KR102626498B1 (ko) 2024-01-19
TWI839055B (zh) 2024-04-11
JP2022082777A (ja) 2022-06-02
AU2017237186B2 (en) 2024-06-20
JP7073266B2 (ja) 2022-05-23

Similar Documents

Publication Publication Date Title
MA43835A (fr) Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP3421503A4 (fr) Procédé de préparation et de purification de sugammadex
EP3434645A4 (fr) Procédé de préparation en continu de nanoplaquettes d'oxyde de graphène
EP3303413A4 (fr) Procédés de préparation de sugammadex et de ses intermédiaires
EP3448918A4 (fr) Procédé de préparation de résines d'organopolysiloxane
EP3398960A4 (fr) Procédé de préparation du sermaglutide
EP3435788A4 (fr) Comprimés bicouches de vitamines et leur procédé de préparation
EP3434262A4 (fr) Procédé de préparation de microgranules à libération prolongée
EP3305310A4 (fr) Formulation virale oncolytique et son procédé de préparation
EP3383436A4 (fr) Procédé amélioré de préparation de vert d'indocyanine
MA45154A (fr) Procédés de préparation d'oligomères
EP3556769A4 (fr) Dérivé de polyximine, procédé de préparation et application associés
EP3528787A4 (fr) Formulations pharmaceutiques et leurs procédés de préparation
EP3372596A4 (fr) Procédé de préparation de tédizolide, intermédiaire de tédizolide et procédé pour sa préparation
EP3653202A4 (fr) Préparation pharmaceutique et son procédé de préparation
EP3351551A4 (fr) Procédé de préparation de promédicaments de phosphoramidate de nucléoside et produits intermédiaires correspondants
EP3398615A4 (fr) Composition pharmaceutique mucoadhésive et son procédé de préparation
EP3402837A4 (fr) Procédé de préparation de nanocomposite de polyéthylène
EP3388424A4 (fr) Procédé de préparation de médicaments lcz696 contre l'insuffisance cardiaque
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
EP3431520A4 (fr) Procédé de préparation d'un copolymère d'oxyméthylène
EP3415552A4 (fr) Procédé de préparation d'une résine superabsorbante et résine superabsorbante
EP3342419A4 (fr) Composition de médecine chinoise traditionnelle anti-acné et son procédé de préparation
EP3445370A4 (fr) Procédés de préparation d'acide obéticholique et de dérivés de celui-ci